Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KDM4A | O75164 | 2/20 | 0.62 |
| ▸ | KDM4B | O94953 | 2/20 | 0.62 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.62 |
| ▸ | KDM5C | P41229 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662898 | 0.95 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29978107 | 0.95 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29978632 | 0.91 | L3MBTL1 (0.69) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL666048 | 0.91 | L3MBTL1 (0.69) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29978328 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL666355 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL663488 | 0.86 | L3MBTL1 (0.67) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29977722 | 0.86 | L3MBTL1 (0.67) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL662890 | 0.84 | ADORA3 (0.63) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL16269991 | 0.83 | MAPT (0.62) | SMN1; SMN2MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2403499-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | Stemsynergy Therapeutics, Inc (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101964-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101964-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | SMN1; SMN2 3313/4885MAPT 3825/4885LMNA 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.